Charts

Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares increased by 114.3% to $1.05 during Monday's pre-market session. The company's ...

Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday. Entera ...

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company’s Special Meeting of Stockholders (the “Special Meeting”) held earlier today.

Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), in advance of the Company’s upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for March 2, 2023.

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services (“ISS”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company’s upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for March 2, 2023. ISS is widely recognized as a leading independent proxy advisory firm, providing impartial analyses and reports to help investors make informed investment decisions.

Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carisma”) management team on Tuesday, February 21, 2023, at 8:00 am ET. The discussion will cover Sesen Bio’s pending merger with Carisma, as well as Carisma’s corporate strategy and clinical programs. Sesen Bio stockholders can submit questions in advance to [email protected].

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that BML Investment Partners, L.P. (“BML”), one of Sesen Bio’s top stockholders, intends to vote all of its shares in support of the Company’s pending merger with Carisma Therapeutics Inc. (“Carisma”).

Gainers Blue Water Vaccines (NASDAQ:BWV) stock moved upwards by 46.1% to $1.71 during Tuesday's regular session. Trading volume for ...

Gainers Rubius Therapeutics (NASDAQ:RUBY) stock increased by 31.5% to $0.25 during Tuesday's pre-market session. The company's market ...

Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the companies have reached a voting and support agreement (the “Support Agreement”) with Bradley L. Radoff and Michael Torok (together with their respective affiliates, the “Investor Group”). The Investor Group, which beneficially owns approximately 8.7% of Sesen Bio’s outstanding common stock, has committed to vote its shares in support of the pending merger.

Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. (“Carisma”). The presentation can be found at www.SesenBioandCarisma.com.

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”) today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’s common stock is subject to delisting.

Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the “Investor Group”):

Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio”), today issued the following open letter to the Boards of Directors (collectively, the “Boards”) of Sesen Bio and Carisma Therapeutics Inc. (“Carisma” and together with Sesen Bio, the “Companies”):

Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about January 24, 2023.

Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today issued the following open letter to the Company’s Board of Directors (the “Board”) regarding the proposed merger with Carisma Therapeutics Inc. (“Carisma”):

Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) as the best path forward for stockholders.

Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today reiterated their intent to vote AGAINST the Company’s proposed merger with Carisma Therapeutics Inc. (“Carisma”) through the following statement:

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 300 points on Friday. The Dow traded down ...

Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its ...

Sesen Bio Inc (NASDAQ: SESN) shares are trading higher by 16.81% to $0.59 Friday morning after the company and Carisma Therapeutics ...

Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares rose 105% to $0.41 in pre-market trading after the company requested to ...

With US stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: Uxin ...

Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced an amendment to their previously announced merger agreement dated September 20, 2022.

Sesen Bio (NASDAQ:SESN) reported its Q3 earnings results on Monday, November 7, 2022 at 08:00 AM. Here's what investors need to ...

Sesen Bio (Nasdaq: SESN) today reported operating results for the third quarter ended September 30, 2022, and provided a business update.

Gainers Adamis Pharmaceuticals (NASDAQ:ADMP) stock rose 41.7% to $0.21 during Tuesday's after-market session. Today's trading volume ...

Gainers Stabilis Solutions, Inc. (NASDAQ: SLNG) shares climbed 71.3% to close at $8.84 after the company announced it has ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sesen Bio, Inc. (NasdaqCM: SESN) (the “Company”) with Carisma Therapeutics Inc., pursuant to which pre-merger Sesen Bio shareholders are expected to own approximately 41.7% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

U.S. stocks traded slightly higher toward the end of trading session on Wednesday following the announcement of interest rate decision ...

Gainers Stabilis Solutions, Inc. (NASDAQ: SLNG) shares jumped 108% to $10.73 after the company announced it has received ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. The Dow traded up ...

In trading on Wednesday, drugs shares were relative laggards, down on the day by about 1.3%. Helping drag down the group were shares of Adamis Pharmaceuticals, off about 41.4% and shares of Sesen Bio down about 38.7% on the day.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sesen Bio, Inc. (NASDAQ: SESN) and Carisma Therapeutics Inc. is fair to Sesen Bio shareholders. Pre-merger Sesen Bio shareholders are expected to own approximately 41.7% of the combined company.

Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and other serious disorders. Carisma is pioneering the development of chimeric antigen receptor macrophage (CAR-M) therapies and is believed to be the only company developing CAR-M therapies with demonstrated proof of mechanism and safety data in clinical trials. The combined company is expected to operate under the name Carisma Therapeutics Inc. and trade on Nasdaq under the ticker symbol “CARM”.

Sesen Bio (NASDAQ:SESN) reported its Q2 earnings results on Monday, August 8, 2022 at 08:00 AM. Here's what investors ...

Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of its lead asset, Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC), and turned its primary focus to the assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022.

Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced ...

U.S. stocks turned lower toward the end of trading, with the Dow Jones dropping around 80 points on Monday. The Dow traded down 0.26% ...

Gainers Calyxt (NASDAQ:CLXT) stock moved upwards by 21.5% to $0.25 during Monday's regular session. The current ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.55% ...

Gainers Intelligent Living Application Group Inc. (NASDAQ: ILAG) shares jumped 90.2% to $4.2792 after declining 11% on Friday. ...

The stock market started the week with gains, led by solid earnings reports from financial companies, including Goldman Sachs.

Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66Monday morning after the company announced that it has made ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Sesen Bio To Pause Clinical ...

Based on a thorough reassessmentSesen Bio Inc(NASDAQ: SESN) hasdecided to voluntarily pausefurther ...

Sesen Bio (Nasdaq: SESN) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC), following recent discussions with the US Food & Drug Administration (FDA). This decision enables Sesen Bio to conserve cash while it continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Additionally, the Company intends to seek a partner for the further development of Vicineum.

How do you go about choosing a stock to buy in these volatile times? One strategy is to look for stocks that are not only selling below their book value, but also below their cash per share, especially if the company has low or no debt.